Cowealth Medical China Co (SHSE:603122) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cowealth Medical China Co EBITDA Margin % Related Terms
Cowealth Medical China Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603122 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Cowealth Medical China Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical China Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cowealth Medical China Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cowealth Medical China Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cowealth Medical China Co (SHSE:603122) has a EBITDA Margin % of -5.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cowealth Medical China Co and its competitors. According to the industry distribution chart, Cowealth Medical China Co ranks #123 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 60.6%.
Is Cowealth Medical China Co's EBITDA Margin % too high?
Cowealth Medical China Co's current EBITDA Margin % is -5.42%. Based on the distribution chart, Cowealth Medical China Co ranks #123 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cowealth Medical China Co has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical China Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cowealth Medical China Co ranks #123 out of 203 companies for EBITDA Margin %. This places Cowealth Medical China Co in the lower half of its industry. The industry median EBITDA Margin % is 5.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cowealth Medical China Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cowealth Medical China Co's current EBITDA Margin % is -5.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical China Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical China Co (SHSE:603122) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.90, compared to a current price of ¥10.96 — trading 181% above its estimated fair value. The current EBITDA Margin % is -5.42%. Cowealth Medical China Co's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cowealth Medical China Co (SHSE:603122), the current EBITDA Margin % is -5.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical China Co (SHSE:603122) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical China Co stock appears to be overvalued.
The current stock price of ¥10.96 is trading 181% above its estimated GF Value™ of ¥3.90.
GuruFocus considers Cowealth Medical China Co to be Significantly Overvalued.
Key valuation signals for SHSE:603122:
EBITDA Margin %: -5.42%
GF Value™: ¥3.90 vs. price of ¥10.96 (181% above fair value)
No single metric tells the full story. See the SHSE:603122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603122 has been successfully added to your 
